Neutralizing Monoclonal Antibody Combo Treats Mild, Moderate COVID - 19

For those at high risk, COVID - 19 - related hospitalization or death from any cause reduced with bamlanivimab/etesevimab versus placebo
Source: Pulmonary Medicine News - Doctors Lounge - Category: Respiratory Medicine Tags: Infections, Internal Medicine, Critical Care, Emergency Medicine, Pharmacy, Pulmonology, Geriatrics, Journal, Source Type: news